Couverture de The Onco'Zine Brief

The Onco'Zine Brief

The Onco'Zine Brief

De : Peter Hofland
Écouter gratuitement

À propos de ce contenu audio

 The Onco'Zine Brief is an interview and discussion program presented by Peter Hofland and covers a broad range of topics and timely news updates with information from all oncology disciplines and sub-specialties from around the world.

The Onco'Zine Brief is a sponsor-supported, program for healthcare professionals involved in the management and care of cancer patients as well as cancer patients and their family and friends. If you like to join us as a sponsor or advertisers, download our media kit (https://adc.expert/oncozine_media_kit).

If you are living in the US, sign up for our newsletter by texting the words CANCER to 66866.

Become a supporter of this podcast: https://www.spreaker.com/podcast/the-onco-zine-brief--2786156/support.Copyright Sunvalley Communication, LLC Hygiène et vie saine Science
Épisodes
  • COVID-19 and the Impact of Cryopreservation on Hematopoietic Cell Grafts

    COVID-19 and the Impact of Cryopreservation on Hematopoietic Cell Grafts
    Nov 30 2023
    In this episode of The Onco’Zine Brief Peter Hofland talks with Stephen Spellman. Stephen Spellman is Vice President and Senior Scientific Director at Be The Match and the Center for International Blood & Marrow Transplant Research (CIBMTR). Hofland and Spellman talk about the outcomes of a study published in Blood Advances, the journal of the American Society of Hematology. [1] The article discusses the impact of cryopreservation of hematopoietic cell grafts on overall survival (OS) and other outcomes within 1 year after hematopoietic cell transplantation. At the beginning of the COVID-19 pandemic the National Marrow Donor Program as together with other national and international donor registries mandated the cryopreservation of hematopoietic cell grafts during the first 6 months of the pandemic because of patient and donor safety concerns. The reason was that during the early days of the pandemic, delivery of donor products after patient conditioning could not be guaranteed. This was, in part, caused by logistical complexities including travel bans, flight delays and cancellations, rerouting of couriers – as well as closed border crossings… In addition, donors were at risk of being infected with the SARS CoV-2 Virus, the virus that causes COVID-19, which, in turn, resulted in last-minute cancellations of graft collection. To solve the pandemic-related logistical problems, the authors of the study conclude that cryopreservation should be considered a method to eliminate the potential risks with the use of fresh donor graft products or when fresh grafts are not available.But what was the impact of cryopreservation on patients receiving hematopoietic cell transplantation compared to the effects among patients receiving fresh donor products? Was there a difference in overall survival, disease free survival, or disease recurrence? Was there a risk in Graft vs Host Disease? In this episode of The Onco’Zine Brief Hofland and Spellman talk about this and more.Reference[1] Devine SM, Bo-Subait S, Kuxhausen M, Spellman SR, Bupp C, Ahn KW, Stefanski HE, Auletta JJ, Logan BR, Shaw BE. Clinical impact of cryopreservation of allogeneic hematopoietic cell grafts during the onset of the COVID-19 pandemic. Blood Adv. 2023 Oct 10;7(19):5982-5993. doi: 10.1182/bloodadvances.2023009786. PMID: 37036959; PMCID: PMC10580174. [Article][Pubmed]About The Onco'Zine BriefThe Onco’Zine Brief is developed in collaboration with our online journal Onco’Zine, where you can find additional information and the latest news about cancer diagnosis and treatment, and cancer prevention.The Onco'Zine Brief is distributed in the United States via PRX (Public Radio Exchange). In the United Kingdom and Europe, the program is distributed via UK Health Radio (UKHR). And the program can be downloaded via most podcasts and streaming media services, including iTunes, Spotify, TuneIn, and iHeart Radio.For more information about The Onco'Zine Brief or how to sponsor or support this public radio broadcast and podcast, visit to download our Media Kit, visit our Patreon page, or contact the sales team.To sign up for The Onco'Zine Newsletter (open for residents of the United States only), text the word CANCER to 66866.Support for The Onco’Zine Brief comes from the Oncology Directory and from listeners like you. Funding is also provided by Java Original Coffee and RoastMasterz.Become a supporter of this podcast: https://www.spreaker.com/podcast/the-onco-zine-brief--2786156/support.
    Afficher plus Afficher moins
    46 min
  • SonALAsense: Developing a Safe and Effective Noninvasive Treatment for Cancer.

    SonALAsense: Developing a Safe and Effective Noninvasive Treatment for Cancer.
    Oct 5 2023
    In a new episode of The Onco’Zine Brief, Peter Hofland talks with Ely Benaim, MD, the Chief Medical Officer and Executive Vice President Development at SonALAsense and Mark De Souza, Ph.D, President and Chief Executive Officer of SonALAsense.

    SonALAsense was founded to create hope in the face of despair with Sonodynamic Therapy (SDT), a non-invasive therapy option using SONALA-001 in combination with Insightec’s MR-guided focused ultrasound (MRgFUS) to treat and eradicate deadly cancers like High-Grade Gliomas (HGG) that typically require debilitating brain surgery that often leads to tumor recurrence.

    SonALAsense’s SDT uses SONALA-001, a proprietary formulation of aminolevulinic acid (ALA), to disrupt heme metabolism in tumor cells, increasing production of protoporphyrin, a heme precursor. From there, energy from focused ultrasound excites protoporphyrin molecules, which produce reactive oxygen species that destroy cancer cells.

    Recently, Hasan Syed, MD, at Children’s National Hospital published a peer-reviewed paper on the first DIPG patient treated with SONALA-001 in the Journal of Neuro-Oncology; a major milestone for this deadly and understudied childhood disease. [1]

    Hofland, Benaim and De Souza talk about new technologies in the treatment of difficult to treat cancers.

    Reference
    [1] Syed HR, Kilburn L, Fonseca A, Nazarian J, Oluigbo C, Myseros JS, Packer RJ, Keating RF. First-in-human sonodynamic therapy with ALA for pediatric diffuse intrinsic pontine glioma: a phase 1/2 study using low-intensity focused ultrasound : Technical communication. J Neurooncol. 2023 Apr;162(2):449-451. doi: 10.1007/s11060-023-04269-8. Epub 2023 Apr 12. PMID: 37046110.

    About The Onco'Zine Brief
    The Onco'Zine Brief is distributed in the United States via PRX (Public Radio Exchange). In the United Kingdom and Europe, the program is distributed via UK Health Radio (UKHR). And the program can be downloaded via most podcasts and streaming media services, including iTunes, Spotify, TuneIn, and iHeart Radio.

    For more information about The Onco'Zine Brief or how to sponsor or support this public radio broadcast and podcast, visit to download our Media Kit, visit our Patreon page, or contact the sales team.

    To sign up for The Onco'Zine Newsletter (open for residents of the United States only), text the word CANCER to 66866.

    The Onco’Zine Brief is made possible, in part, by Java Original Coffee and Roastmasterz by Java Original Coffee.

    Become a supporter of this podcast: https://www.spreaker.com/podcast/the-onco-zine-brief--2786156/support.
    Afficher plus Afficher moins
    49 min
  • Be The Match®: Improving Outcomes and Providing Hope to Patients in Need

    Be The Match®: Improving Outcomes and Providing Hope to Patients in Need
    Sep 28 2023
    In a new episode of The Onco’Zine Brief, Peter Hofland talks with Jeffery Auletta, MD is Senior Vice President, Patient Outcomes and Experience, National Marrow Donor Program® (NMDP)/Be The Match®.

    Be The Match® is a global leader in bone marrow transplantation. The organization conducts research to improve transplant outcomes provide support and resources for patients, and partner with a global network.

    Unmet medical need
    Every three or four minutes, someone in the United States is diagnosed with a hematological malignancy such as leukemia, a cancer of blood-forming tissues, including bone marrow.

    For many patients, their only hope for a cure is a stem cell transplant. In the program, Hofland and Auletta talk about these unmet medical needs and about the new developments exploring the use of a standardized method of assessing measurable residual disease (MRD) before allogeneic hematopoietic stem cell transplantation (HCT) in patients with leukemia and how this provides valuable insight into MRD as a predictive tool to inform HCT decisions and individualize treatment to improve outcomes.

    Hofland and Auletta also talk about the importance of people to join and register with Be The Match® as a bone marrow donor to bring hope to people in need.

    About The Onco'Zine Brief
    The Onco'Zine Brief is distributed in the United States via PRX (Public Radio Exchange). In the United Kingdom and Europe, the program is distributed via UK Health Radio (UKHR). And the program can be downloaded via most podcasts and streaming media services, including iTunes, Spotify, TuneIn, and iHeart Radio.

    For more information about The Onco'Zine Brief or how to sponsor or support this public radio broadcast and podcast, visit to download our Media Kit, visit our Patreon page, or contact the sales team.

    To sign up for The Onco'Zine Newsletter (open for residents of the United States only), text the word CANCER to 66866.

    The Onco’Zine Brief is made possible, in part, by Java Original Coffee and Roastmasterz by Java Original Coffee.


    Become a supporter of this podcast: https://www.spreaker.com/podcast/the-onco-zine-brief--2786156/support.
    Afficher plus Afficher moins
    52 min
Aucun commentaire pour le moment